Raj L Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raj L Mehta has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Calvin Bateman
Department of Cellular Pathology University Hospital Southampton NHS Foundation Trust Southampton UK
1 shared publication - Bernard Sf Stacey
Department of Gastroenterology, Southampton University Hospital, Southampton, SO166YD, UK
1 shared publication - Federica Di Nicolantonio
Department of Oncology, University of Torino, Torino, Italy
1 shared publication - Ian A. Cree
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
1 shared publication - Penny Johnson
Translational Oncology Research Centre, Queen Alexandra Hospital, PO6 3LY Portsmouth, UK
1 shared publication - Pradeep Bhandari
Gastoenterology, Queen Alexandra Hospital, Portsmouth, UK
1 shared publication
Latest Publications
- Open Access
- 19 May 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 134
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus
COX-2 expression in tumour cells has been associated with poor prognosis in gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic features in adenocarcinoma of the oesophagus. We reviewed the records of 100 consecutive patients undergoing resection for adenocarcinoma of the oesophagus to collect data on T-stage, N-stage, tumour recurrence and survival. T & N-stage was further confirmed by histological examination. COX-2 protein expression was assessed by immunohistochemistry in all patients and COX-2 m-RNA expression was measured by quantitative RT-PCR in a small group of patients. Higher levels of COX-2 expression were associated with higher T stage (p = 0.008), higher N stage (p = 0.049), increased risk of tumour recurrence (p = 0.01) and poor survival (p = 200 was associated with a median survival of 10 months compared to 26 months with a score of <200 (p = <0.001). Higher levels of COX-2 expression are associated with poor clinico-pathologic features and poor survival in patients with oesophageal adenocarcinoma.
- 19 May 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 134
Open AccessPrognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus
COX-2 expression in tumour cells has been associated with poor prognosis in gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic features in adenocarcinoma of the oesophagus. We reviewed the records of 100 consecutive patients undergoing resection for adenocarcinoma of the oesophagus to collect data on T-stage, N-stage, tumour recurrence and survival. T & N-stage was further confirmed by histological examination. COX-2 protein expression was assessed by immunohistochemistry in all patients and COX-2 m-RNA expression was measured by quantitative RT-PCR in a small group of patients. Higher levels of COX-2 expression were associated with higher T stage (p = 0.008), higher N stage (p = 0.049), increased risk of tumour recurrence (p = 0.01) and poor survival (p = 200 was associated with a median survival of 10 months compared to 26 months with a score of <200 (p = <0.001). Higher levels of COX-2 expression are associated with poor clinico-pathologic features and poor survival in patients with oesophageal adenocarcinoma.